NCT Number: NCT02183220
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male and female patients between 18 and 65 years old
- Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
- At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
- The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
- First episodic headache occurred at an age under 50 years
- Written informed consent according to Good Clinical Practice (GCP) and local regulations
- The patient was able to fill in the Patient's Diary
Exclusion criteria
- The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
- The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
- The patient has more than 15 episodes of tension headache per month
- Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception
- Concomitant treatment with (non-) prescriptional analgesics
- Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
- Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
- Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
- Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
- Concomitant treatment with any drug containing ASA and/or metamizol
- Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
- Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders )
- Female patients in child-bearing age not using adequate means of birth control
- Pregnancy and/or lactation
- Gastrointestinal ulcers
- Liver and/or renal disease
- Bronchial asthma
- Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs
- Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
- Patients with active gastroesophageal flux disease (Amendment number 1)
- Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)
Treatment and study plan
Acetylsalicylic acid (ASA)
DrugMetamizol placebo
DrugASA placebo
DrugPrimary outcomes
-
Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)
Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Secondary outcomes
-
Pain intensity difference (PID) on a VAS
Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
-
Maximum pain intensity difference (MAXPID) on a VAS
Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
-
Number of patients with at least a 50% pain reduction on a VAS
Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
-
Time to 50% pain intensity reduction on a VAS
Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
-
Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)
Time frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake
-
Total pain relief (TOTPAR) on a VRS
Time frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake
-
Number of patients using rescue medication
Time frame: 2, 3, and 4 hours after drug intake
-
Global efficacy assessment on a VRS by the patient and investigator
Time frame: 4 hours after drug intake
-
Number of patients with adverse events
Time frame: up to 2 months
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.
Important dates
- Study start
- 1998
- Primary completion
- 1999
- First posted
- Jul 8, 2014
- Registry last updated
- Jul 8, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Intervention for Sleep and Pain in Youth: A Randomized Controlled Trial
NCT04936321
Brain Diseases, Central Nervous System Diseases
Seattle, Washington, United States
View Trial DetailsMigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine
NCT03157739
Brain Diseases, Central Nervous System Diseases
Cincinnati, Ohio, United States
View Trial DetailsVideonystagmography and Vestibular Migraine
NCT07000929
Brain Diseases, Central Nervous System Diseases
Essen, North Rhine-Westphalia, Germany
View Trial DetailsEmotional Awareness and Expression Therapy (EAET) as a Novel Migraine Treatment
NCT05837650
Brain Diseases, Central Nervous System Diseases
Salt Lake City, Utah, United States
View Trial Details